• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利用肺动脉高压临床站点和患者视角（PERSIST）影响马昔腾坦和司来帕格患者持续治疗率的实践：一项美国定性分析

Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis.

作者信息

Shlobin Oksana A, Bruce Gary, Gomez-Rendon Gabriela, Kingman Martha, Rahman Mohammad, Rogers Frances, Studer Sean, Tobore Tobore, McEvoy Colleen

机构信息

Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA.

Patient author Dallas Texas USA.

出版信息

Pulm Circ. 2024 Oct 11;14(4):e12441. doi: 10.1002/pul2.12441. eCollection 2024 Oct.

DOI:10.1002/pul2.12441
PMID:39398324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11467788/
Abstract

This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

摘要

这项真实世界研究从23名医疗保健专业人员（HCPs）和134名肺动脉高压患者的角度，探讨了2019年至2022年期间影响马昔腾坦和司来帕格治疗持续性的因素。患者/医疗保健专业人员之间持续的沟通和教育是治疗持续性的关键驱动因素，副作用的早期讨论和管理也是如此。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11467788/6b34e975dc5a/PUL2-14-e12441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11467788/6b34e975dc5a/PUL2-14-e12441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c8e/11467788/6b34e975dc5a/PUL2-14-e12441-g001.jpg

相似文献

1
Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis.利用肺动脉高压临床站点和患者视角（PERSIST）影响马昔腾坦和司来帕格患者持续治疗率的实践：一项美国定性分析
Pulm Circ. 2024 Oct 11;14(4):e12441. doi: 10.1002/pul2.12441. eCollection 2024 Oct.
2
Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report.麦格司他坦和塞乐西帕引起肝毒性的药物咨询：1 例报告。
J Med Case Rep. 2022 Oct 18;16(1):385. doi: 10.1186/s13256-022-03571-9.
3
Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension.司来帕格联合治疗肺动脉高压的成本效益分析
Front Pharmacol. 2023 Aug 11;14:1122866. doi: 10.3389/fphar.2023.1122866. eCollection 2023.
4
Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　- Protocol of a Multicenter Randomized Control Trial.马昔腾坦联合利奥西呱或马昔腾坦联合司来帕格双重初始联合治疗对肺动脉高压患者血流动力学的影响（SETOUCHI-PH研究）——一项多中心随机对照试验方案
Circ Rep. 2021 Jan 9;3(2):105-109. doi: 10.1253/circrep.CR-20-0133.
5
Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.采用国家癌症研究所患者报告结局版通用不良事件术语标准评估肺动脉高压治疗耐受性：口服塞乐西帕的现用和曾用患者定性研究结果。
J Patient Rep Outcomes. 2023 Dec 18;7(1):134. doi: 10.1186/s41687-023-00673-w.
6
Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry).真实世界登记研究 SPHERE 中使用塞乐西帕治疗的肺动脉高压患者的疾病特征、治疗方法和结局（塞乐西帕：使用者药物登记研究）。
J Heart Lung Transplant. 2024 Feb;43(2):272-283. doi: 10.1016/j.healun.2023.09.016. Epub 2023 Sep 29.
7
Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.接受口服司来帕格、吸入伊洛前列素或肠外曲前列尼尔治疗的肺动脉高压患者的医疗接触与药物持续性比较：一项回顾性数据库分析
J Health Econ Outcomes Res. 2022 Jun 8;9(1):151-160. doi: 10.36469/001c.35246. eCollection 2022.
8
Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.日本肺动脉高压患者使用内皮素受体拮抗剂的治疗持续性和依从性比较：一项基于真实世界管理索赔数据库的研究
Pulm Ther. 2023 Dec;9(4):511-526. doi: 10.1007/s41030-023-00244-w. Epub 2023 Nov 22.
9
Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.三重口服联合疗法治疗肺动脉高压：马西替坦、利奥西呱和塞乐西帕。
Ther Adv Respir Dis. 2021 Jan-Dec;15:1753466621995048. doi: 10.1177/1753466621995048.
10
Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.在一名接受三联联合治疗的特发性肺动脉高压患者中，从口服司来帕格安全且成功地过渡到皮下注射曲前列尼尔。
J Cardiol Cases. 2022 Mar 22;26(1):42-45. doi: 10.1016/j.jccase.2022.02.003. eCollection 2022 Jul.

引用本文的文献

1
Real-World Adherence and Persistence of Upfront Therapy in Patients with Pulmonary Arterial Hypertension in the United States.美国肺动脉高压患者初始治疗的真实世界依从性和持续性
Pulm Ther. 2025 Sep 6. doi: 10.1007/s41030-025-00311-4.
2
Patient Perspectives on Fixed Dose Combination Therapy for Pulmonary Arterial Hypertension: Exploratory Focus Group Research.肺动脉高压患者对固定剂量联合治疗的看法：探索性焦点小组研究
Pulm Circ. 2025 May 28;15(2):e70098. doi: 10.1002/pul2.70098. eCollection 2025 Apr.

本文引用的文献

1
Adherence and Discontinuation of Disease-Specific Therapies for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.肺动脉高压疾病特异性疗法的依从性与停药情况：一项系统评价与荟萃分析
Am J Cardiovasc Drugs. 2023 Jan;23(1):19-33. doi: 10.1007/s40256-022-00553-6. Epub 2022 Nov 25.
2
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
3
Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy.
利用真实世界证据描述肺动脉高压的治疗模式、医疗资源利用情况以及与磷酸二酯酶-5抑制剂单药治疗相关的成本。
J Health Econ Outcomes Res. 2018 Jan 9;5(2):206-219. doi: 10.36469/9812. eCollection 2018.
4
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.肺动脉高压或慢性血栓栓塞性肺动脉高压患者对疾病特异性药物治疗的依从性。
ERJ Open Res. 2020 Dec 7;6(4). doi: 10.1183/23120541.00299-2020. eCollection 2020 Oct.
5
High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach.肺动脉高压患者的高药物依从率：综合专业药房方法。
PLoS One. 2019 Jun 6;14(6):e0217798. doi: 10.1371/journal.pone.0217798. eCollection 2019.
6
Selexipag for the Treatment of Pulmonary Arterial Hypertension.塞乐西帕用于肺动脉高压的治疗。
N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.
7
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.马西替坦对住院的影响：SERAPHIN 试验的结果。
JACC Heart Fail. 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11.
8
Macitentan and morbidity and mortality in pulmonary arterial hypertension.马西替坦治疗肺动脉高压的发病率和死亡率。
N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.
9
Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.与磷酸二酯酶 5 抑制剂治疗肺动脉高压的依从性相关的因素。
J Med Econ. 2013;16(2):298-306. doi: 10.3111/13696998.2012.756399. Epub 2012 Dec 12.
10
Medication compliance and persistence: terminology and definitions.药物依从性和持续性：术语与定义。
Value Health. 2008 Jan-Feb;11(1):44-7. doi: 10.1111/j.1524-4733.2007.00213.x.